中国临床药理学与治疗学2025，Vol.30Issue(12)：1632-1639,8.DOI:10.12092/j.issn.1009-2501.2025.12.006
多巴胺去甲肾上腺素再摄取抑制剂治疗日间过度思睡研究进展
Research progress on dopamine and norepinephrine reuptake inhibi-tors for the treatment of excessive daytime sleepiness
摘要
Abstract
Excessive daytime sleepiness(EDS)is characterized by failure to maintain wakefulness and alertness,with a compelling need to sleep and may even fall asleep involuntarily.It is often accom-panied by deficits in attention and memory,im-pairs daily functioning,and poses safety risks.Dys-regulation of monoaminergic arousal pathways-par-ticularly noradrenergic and dopaminergic systems—is closely implicated.Although several commonly used agents act via monoamine reuptake inhibi-tion,only solriamfetol,a selective dopamine-nor-epinephrine reuptake inhibitor(DNRI),currently has clear evidence supporting efficacy for EDS asso-ciated with narcolepsy and obstructive sleep apnea(OSA).As a selective dopamine and norepinephrine reuptake inhibitor(DNRI),solriamfetol exerts its wake-promoting effects by blocking the corre-sponding transporters,thereby increasing mono-amine levels in the synaptic cleft.Results from mul-tiple clinical trials indicate that solriamfetol signifi-cantly improves patients'subjective sleepiness scores and objective ability to maintain wakeful-ness,with an overall favorable safety profile and no observed rebound sleepiness or withdrawal reac-tions.Real-world studies further confirm the feasi-bility of its long-term use.Against the backdrop of the mechanism of action and clinical application of monoamine reuptake inhibitors,this article focuses on reviewing the pharmacological characteristics of solriamfetol and its clinical research progress in both approved and investigational indications,aim-ing to provide evidence-based references for per-sonalized wake-promoting treatment strategies in patients with EDS as a core phenotype.关键词
索安非托/日间过度思睡/发作性睡病/阻塞性睡眠呼吸暂停Key words
solriamfetol/excessive daytime sleep-iness/narcolepsy/obstructive sleep apnea分类
医药卫生引用本文复制引用
张斌,辛倩倩,黄豪康..多巴胺去甲肾上腺素再摄取抑制剂治疗日间过度思睡研究进展[J].中国临床药理学与治疗学,2025,30(12):1632-1639,8.基金项目
南方医科大学南方医院临床研究专项(2021CR009) （2021CR009）
国家重点研发计划(2021YFC2501500) （2021YFC2501500）
